344 research outputs found
Minimal free resolutions, Hilbert functions and the graded Betti numbers - by Rana Rizkallah Sabbagh
No full textThesis (M.S.)--American University of Beirut, Dept. of Mathematics, 2009.;"Advisor : Dr. El Khoury Sabine, Assistant Professor, Mathematics--Member of Committee : Dr. Abu Khuzam Hazar, Professor , Mathematics--Member of Committee : Dr. Nahlus Nazih, ProfeBibliography : leaf 47.This thesis discusses the connection between the Hilbert function, graded Betti numbers and minimal free resolutions. In our first chapter we let R be a Noether ian local ring and M its maximal ideal. We define in general, the minimal free r esolution o
Natural killer cell immunoglobulin-like receptor (KIR) genotypes in follicular lymphoma patients: Results of a pilot study
No full textAims: The Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotype profiling in Follicular Lymphoma has not been reported before in the literature. Materials and methods: DNA extracted from 20 Follicular Lymphoma patients and 62 healthy controls was analyzed for KIR genotyping using a polymerase chain reaction-sequence specific primers technique (PCR-SSP) for the presence of 16 KIR gene and pseudogene loci. Results: The AA, AB, and BB genotype frequencies were, respectively, 20percent, 60percent and 20percent with an A:B ratio of 1:1. KIR 2DL4, KIR 3DL2, KIR 3DL3, and KIR 3DP1*. 003 were presented in all individuals. No significant difference between patients and controls was detected. Conclusion: KIR genotyping profile does not seem to be associated with Follicular Lymphoma. The results presented in this pilot research represent the first international report about this important clinical entity. © 2013 Elsevier B.V.AMAKAWA R, 1989, BLOOD, V73, P787; Chan WC, 1997, BLOOD, V89, P3909; BANERJEE D, 1983, NATURE, V304, P270, DOI 10.1038-304270a0; Bitar M, 2008, GENET TEST, V12, P517, DOI 10.1089-gte.2008.0033; Cheson BD, 2004, CA-CANCER J CLIN, V54, P260; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056-NEJMra041720; Dukers DF, 2001, J CLIN PATHOL, V54, P224, DOI 10.1136-jcp.54.3.224; Ferlazzo G, 2004, J IMMUNOL, V172, P1455; Ghielmini M, 2010, ANN ONCOL, V21, P151, DOI 10.1093-annonc-mdq287; GULLEY ML, 1992, CANCER, V69, P1600, DOI 10.1002-1097-0142(19920315)69:6+1600::AID-CNCR28206913163.0.CO;2-#; Haedicke W, 2000, BLOOD, V95, P3628; Jemal A, 2004, CA-CANCER J CLIN, V54, P8; Knutsen T, 1997, CANCER SURV, V30, P163; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073-pnas.95.9.5199; Mahfouz R, 2011, INT J TUBERC LUNG D, V15, P1688, DOI 10.5588-ijtld.11.0138; Mahfouz R., 2006, MOL BIOL REP, V34, P271; Mahfouz RAR, 2009, GENET TEST MOL BIOMA, V13, P91, DOI 10.1089-gtmb.2008.0081; Morice WG, 2006, LEUKEMIA, V20, P883, DOI 10.1038-sj.leu.2404168; Stern M, 2010, BLOOD, V115, P3960, DOI 10.1182-blood-2009-10-250134; Vermeer MH, 2001, J CLIN ONCOL, V19, P4322; ZELENETZ AD, 1991, ANN ONCOL, V2, P1150
High prevalence of MTHFR gene A1298C polymorphism in Lebanon
No full textBackground: Mutations in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene could reduce the enzyme activity and lead to hyperhomocysteinemia, a condition that has been associated with several vascular conditions, in particular, coronary artery disease and deep vein thrombosis. Aim: The aim of this study was to assess the prevalence of the two most common polymorphisms, C677T and A1298C, which have not been well studied in the Lebanese population. Methods: We randomly selected 205 healthy individuals originating from different Lebanese provinces and religious communities. The CVD StripAssay was used to test for MTHFR gene polymorphisms. Results: We found that for C677T, the prevalence of C-C, C-T, and T-T genotypes was 65.3percent, 30.8percent, and 3.9percent, respectively, with an overall carrier rate of 34.6percent and allelic frequency of 0.19. However, the A1298C genotypic prevalence of A-C, A-A, and C-C was 50.2percent, 25.9percent, and 23.9percent, respectively, with an overall carrier rate of 74.14percent and an allelic frequency of 0.49. Conclusions: Compared to all other populations reported so far, the Lebanese population harbors the highest prevalence of the MTHFR A1298C polymorphism. This is an important finding to be followed in terms of clinical significance and sheds light on an additional unique genetic feature in this community. © Copyright 2008, Mary Ann Liebert, Inc.Al-Habboubi H, 2003, J THROMB HAEMOST, V1, P2246, DOI 10.1046-j.1538-7836.2003.00390.x; Al-Habboubi HH, 2004, THROMB HAEMOSTASIS, V91, P843; Almawi WY, 2004, AM J HEMATOL, V76, P85, DOI 10.1002-ajh.20047; Angeline T, 2004, EXP MOL PATHOL, V77, P85, DOI 10.1016-j.yexmp.2004.04.006; Antoniadi T, 1999, AM J HEMATOL, V61, P265, DOI 10.1002-(SICI)1096-8652(199908)61:4265::AID-AJH83.0.CO;2-#; Arruda VR, 1998, AM J MED GENET, V78, P332, DOI 10.1002-(SICI)1096-8628(19980724)78:4332::AID-AJMG53.0.CO;2-N; Chango A, 2000, BRIT J NUTR, V84, P891; Chiusolo P, 2004, HAEMATOLOGICA, V89, P139; DAngelo A, 1997, HAEMATOLOGICA, V82, P211; DeFranchis R, 1996, AM J HUM GENET, V59, P262; De Marco P, 2002, J HUM GENET, V47, P319, DOI 10.1007-s100380200043; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056-NEJM199603213341203; Eid Suhair S, 2004, Clin Lab Sci, V17, P200; Esfahani ST, 2003, J AM DIET ASSOC, V103, P200, DOI 10.1053-jada.2003.50030; Falchi A, 2005, EXP MOL PATHOL, V79, P210, DOI 10.1016-j.yexmp.2005.09.005; Franco RF, 1998, THROMB HAEMOSTASIS, V79, P119; Friedman G, 1999, J NUTR, V129, P1656; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038-ng0595-111; Gibson CS, 2005, PATHOLOGY, V37, P160, DOI 10.1080-00313020500058250; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001-jama.277.22.1775; Gudnason V, 1998, ATHEROSCLEROSIS, V136, P347, DOI 10.1016-S0021-9150(97)00237-2; Hanson NQ, 2001, CLIN CHEM, V47, P661; Hiraoka M, 2004, BIOCHEM BIOPH RES CO, V316, P1210, DOI 10.1016-j.bbrc.2004.02.174; Kahleova R, 2002, AM J HYPERTENS, V15, P857, DOI 10.1016-S0895-7061(02)02984-9; KANG SS, 1991, AM J HUM GENET, V48, P536; Kiffmeyer WR, 2004, CANCER, V100, P411, DOI 10.1002-cncr.11913; Koch MC, 1998, EUR J PEDIATR, V157, P487, DOI 10.1007-s004310050860; Kostulas K, 1998, EUR J CLIN INVEST, V28, P285; Lu YH, 2002, THROMB RES, V106, P7, DOI 10.1016-S0049-3848(02)00064-6; Mahfouz RAR, 2006, MOL BIOL REP, V33, P145, DOI 10.1007-s11033-006-6260-x; Markan S, 2007, MOL CELL BIOCHEM, V302, P125, DOI 10.1007-s11010-007-9434-5; Mornet E, 1997, HUM GENET, V100, P512, DOI 10.1007-s004390050544; Mutchinick OM, 1999, MOL GENET METAB, V68, P461, DOI 10.1006-mgme.1999.2939; Nishio H, 1996, JPN J HUM GENET, V41, P247, DOI 10.1007-BF01875985; Ou CY, 1996, AM J MED GENET, V63, P610, DOI 10.1002-(SICI)1096-8628(19960628)63:4610::AID-AJMG153.3.CO;2-Y; Peng FY, 2001, INT J MOL MED, V8, P509; Pepe G, 1998, AM J HUM GENET, V63, P917, DOI 10.1086-302015; Perez ABA, 2003, AM J MED GENET A, V119A, P20, DOI 10.1002-ajmg.a.10059; Rady PL, 1999, AM J MED GENET, V86, P380, DOI 10.1002-(SICI)1096-8628(19991008)86:4380::AID-AJMG133.0.CO;2-9; Rosenberg N, 2002, AM J HUM GENET, V70, P758, DOI 10.1086-338932; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; SABBAGH AS, 2006, MOL BIOL REP, V34, P47; Sacchi E, 1997, THROMB HAEMOSTASIS, V78, P963; Sazci A, 2005, CELL BIOCHEM FUNCT, V23, P51, DOI 10.1027-cbf.1132; Shrubsole MJ, 2004, CANCER EPIDEM BIOMAR, V13, P190, DOI 10.1158-1055-9965.EPI-03-0273; Stevenson RE, 1997, AM J HUM GENET, V60, P229; Taher A, 2001, THROMB HAEMOSTASIS, V86, P723; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086-301825; Vanegas OC, 1998, THROMB HAEMOSTASIS, V79, P883; Viel A, 1997, BRIT J CANCER, V75, P1105, DOI 10.1038-bjc.1997.191; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006-mgme.1998.2714; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878; Yoo JH, 2000, THROMB RES, V97, P77, DOI 10.1016-S0049-3848(99)00127-9; Zaatari GS, 2006, PATHOLOGY, V38, P442, DOI 10.1080-00313020600922934; Zetterberg H, 2002, THROMB RES, V108, P127, DOI 10.1016-S0049-3848(03)00004-519191
Frequency of triple mutations involving factor V, prothrombin, and methylenetetrahydrofolate reductase genes among patients referred for molecular thrombophilia workup in a tertiary care center in Lebanon
No full textAim: Molecular diagnostics has markedly improved the diagnosis and workup of different clinical conditions including hypercoagulable state or thrombophilia where different genes are involved. In this report, which is the largest report in the medical literature and the first in Lebanon, we describe the prevalence of simultaneous mutations in the three major thrombophilia genes Factor V, Factor II, and methylenetetrahydrofolate reductase. Materials and Methods: Using a polymerase chain reaction and reverse hybridization assay for the corresponding mutations identification, 2248 referred cases were analyzed. Results: Only 25 cases were found to be simultaneously positive for the three mutations at a prevalence rate of 1.1percent. Conclusion: Compared with other populations, this prevalence rate is considered high, possibly the highest, and warrants future clinical studies and follow-up. © Copyright 2012, Mary Ann Liebert, Inc..Arslan S, 2011, MOL BIOL REP, V38, P2395, DOI 10.1007-s11033-010-0373-y; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Bourouba R, 2009, CLIN APPL THROMB-HEM, V15, P529, DOI 10.1177-1076029608319944; Caramaschi P, 2010, JOINT BONE SPINE, V77, P330, DOI 10.1016-j.jbspin.2010.02.022; Duga S, 2004, INT J BIOCHEM CELL B, V36, P1393, DOI 10.1016-j.biocel.2003.08.002; Ehrenforth S, 1999, ARTERIOSCL THROM VAS, V19, P276; Ehrenforth S, 1998, BLOOD, V91, P2209; Emmerich J, 2001, THROMB HAEMOSTASIS, V86, P809; Jayandharan G, 2005, J THROMB HAEMOST, V3, P1446, DOI 10.1111-j.1538-7836.2005.01402.x; Kfoury E, 2009, MOL BIOL REP, V36, P1041, DOI 10.1007-s11033-008-9278-4; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; Margaglione M, 1999, THROMB HAEMOSTASIS, V82, P1583; Mozafari H, 2009, MOL BIOL REP, V36, P2361, DOI 10.1007-s11033-009-9458-x; Otrock ZK, 2008, ANN HEMATOL, V87, P1013, DOI 10.1007-s00277-008-0543-3; Rahimi Z, 2011, MOL BIOL REP, V38, P2117, DOI 10.1007-s11033-010-0338-1; Rahimi Z, 2011, MOL BIOL REP, V38, P703, DOI 10.1007-s11033-010-0157-4; Sabbagh A, 2009, MOL BIOL REP, V36, P399, DOI 10.1007-s11033-007-9193-0; Sabbagh AS, 2008, GENET TEST, V12, P75, DOI 10.1089-gte.2007.0064; Said JM, 2010, OBSTET GYNECOL, V115, P5, DOI 10.1097-AOG.0b013e3181c68907; Severinsen MT, 2010, BRIT J HAEMATOL, V149, P273, DOI 10.1111-j.1365-2141.2010.08086.x; Simioni P, 2000, BLOOD, V96, P3329; Spiroski I, 2008, CROAT MED J, V49, P39, DOI 10.3325-cmj.2008.1.39; Taher A, 2001, THROMB HAEMOSTASIS, V86, P723; Tatarskyy P, 2010, Tsitol Genet, V44, P3; Zahed LF, 2006, AM J OBSTET GYNECOL, V195, P1114, DOI 10.1016-j.ajog.2006.06.082; Zoller B, 1998, BLOOD, V91, P221021
ADOPTION OF EMERGING TECHNOLOGY TOOLS IN LOGISTICS INDUSTRY: PRIORITIZATION USING ANP AND BOCR METHODS
No full textThis study aims to prioritize technology tools in the logistics industry. It focuses on four key technology trends: Augmented Reality (AR), the Internet of Things (IoT), Big Data, and Robotics and Automation (R&A). The objective is to determine the prioritization and ranking of these technologies in the logistics sector using the Analytic Network Process (ANP) model and analyzing using the Benefits, Opportunities, Costs, and Risks (BOCR) model. The study identified specific criteria and sub-criteria to evaluate the technologies, and experts from the fields provided judgments based on these criteria. Applying the ANP and BOCR models, the research presents the ranking of the technology trends, highlighting their importance and potential impact on the logistics industry. The findings of this research help to gain further knowledge of the technology adoption in the logistics sector and provide valuable insights for industry professionals and decision-makers
Gate-controlled quantum dots and superconductivity in planar germanium
No full textSuperconductors and semiconductors are crucial platforms in the field of quantum computing.
They can be combined to hybrids, bringing together physical properties that enable
the discovery of new emergent phenomena and provide novel strategies for quantum control.
The involved semiconductor materials, however, suffer from disorder, hyperfine interactions
or lack of planar technology. Here we realise an approach that overcomes these issues
altogether and integrate gate-defined quantum dots and superconductivity into germanium
heterostructures. In our system, heavy holes with mobilities exceeding 500,000 cm2 (Vs)−1
are confined in shallow quantum wells that are directly contacted by annealed aluminium
leads. We observe proximity-induced superconductivity in the quantum well and demonstrate
electric gate-control of the supercurrent. Germanium therefore has great promise for
fast and coherent quantum hardware and, being compatible with standard manufacturing,
could become a leading material for quantum information processing
Modern trends in lipomodeling
No full textLipomodeling is the process of relocating autologous fat to change the shape, volume, consistency, and profile of tissues, with the aim of reconstructing, rejuvenating, and regenerating body features. There have been several important advancements in lipomodeling procedures during the last thirty years. Four clinical steps are important for the success of engraftment: fat harvesting, fat processing, fat reinjection, and preconditioning of the recipient site. With the discovery of adipose derived stem cells and dedifferentiated cells, fat cells become a major tool of regenerative medicine. This article reviews recent trends in lipomodeling trying to understand most of the issues in this field
Usage of a rotational flap for coverage of a large central forehead defect
No full textBackground: The forehead is a donor site for facial reconstruction but has no generous donor site for its coverage. All options of the reconstructive ladder can be used. A large rotation flap was used to reconstruct a big central forehead defect following failed previous repair in an elderly diabetic patient after a motor car accident. Case presentation: A 64-year-old diabetic man presented with an extensive central forehead defect after failed previous repair following a motor car accident. Coverage of the defect was performed using a flap based around the ear on one side in a rotation movement. An accepted functional and esthetic result was achieved after 3 months of Conclusion: A rotation flap based on arteries around the ear can be used for coverage of a difficult lesion in the central forehead. Level of evidence: Level V, therapeutic stud
Davis flap: the glory still present
No full textBackground: Upper third defects of the ear are too large to be closed primarily without distorting the auricle. Full thickness defects can be reconstructed with local flaps. In this article, Davis flap was used to fill the upper third defects of the ear with some modifications. Patients and methods: Eight patients underwent reconstruction of full thickness auricular defects with Davis flaps from July 2012 to December 2014. The posterior surface of the flap and the raw area of conchal area were covered by full thickness graft taken from posterior surface of ear.Results: All flaps survived. No congestion was noted. The donor sites and skin grafts healed uneventfully. Conclusion: Davis flap is a simple and reproducible tool for reconstruction of upper third of ear
- …
